Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs

Outeiro-Pinho, Gonçalo; Barros‐Silva, Daniela; Correia, Margareta P.; Henrique, Rui; Jerónimo, Carmen

doi:10.3390/cancers12082214

Cited by 12 publications

(9 citation statements)

References 197 publications

(132 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, ccRCC has been considered as a metabolic disease after integrating molecular profiling studies 7 . Outeiro-Pinho G et al found that ccRCC cell metabolism is dominated by four types of macromolecular changes such as carbohydrates, lipids, amino acids and nucleic acids, which can be jointly involved in the regulation of multiple molecular mechanisms 5 . It also relies on the "reflux" of glutamine metabolism and the tricarboxylic acid cycle, where reductive carboxylation occurs, allowing rapid ATP production, maintaining ccRCC energy and strictly appropriate redox status 8 .…”

Section: Metabolic Reprogramming In Tumor Cellsmentioning

confidence: 99%

“…lncRNAs are large RNA transcripts more than 200 nucleotides in length that regulate cancer cell malignancy by participating in ccRCC cell metabolic reprogramming. They regulate the malignant transformation of cancer cells and control cellular energy metabolism by participating in the "metabolic reprogramming" of ccRCC cells 5 . However, the molecular characteristics and metabolic regulatory mechanisms of lncRNAs in ccRCC are still incomplete.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of Metabolic Reprogramming of Long non-coding RNA in Clear Cell Renal Cell Carcinoma

Zhang¹,

Yu²,

Chen³

et al. 2022

J. Cancer

View full text Add to dashboard Cite

Renal cell carcinoma (RCC), one of the most frequent cancers, is a "classical" malignancy characterized by metabolic reprogramming. Clear cell renal cell carcinoma (ccRCC) is its most common histopathological subtype. Long-stranded non-coding ribonucleic acids (LncRNAs) are regulatory RNA molecules with limited protein-coding capacity and evolutionary conservation. Recent studies have revealed that lncRNAs can broadly regulate the metabolic reprogramming of ccRCC and its malignant transformation. However, there are few studies on lncRNAs regulating the metabolism of ccRCC, and the specific mechanisms are unknown. Therefore, this paper summarizes the regulatory mechanisms of lncRNAs in the metabolism of ccRCC, especially in the pathways of glycolysis, mitochondrial function, glutamine and lipid metabolism, cellular mechanisms, interactions with other molecules, specific scientific and clinic implications and applications to provide a basis for early clinical diagnosis, prediction and treatment. We also discuss the clinical application and challenges of targeting lncRNAs in ccRCC metabolism.

show abstract

Section: Metabolic Reprogramming In Tumor Cellsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Role of Metabolic Reprogramming of Long non-coding RNA in Clear Cell Renal Cell Carcinoma

Zhang¹,

Yu²,

Chen³

et al. 2022

J. Cancer

View full text Add to dashboard Cite

show abstract

“…miRNAs are small non-coding RNAs of approximately 22 nucleotides in length implicated in posttranscriptional regulation of gene expression. miRNAs regulate a wide spectrum of cellular processes acting as oncogene or as tumor suppressors of the genes they regulate [ 134 ]. A number of functional studies have revealed deregulated miRNA (either upregulation or downregulation) involved in cell cycle regulation, apoptosis, cell adhesion, and extracellular matrix or metabolism with a key role in RCC [ 111 , 135 , 136 , 137 ].…”

Section: Epigenetics Of Clear Cell Renal Cell Carcinomamentioning

confidence: 99%

The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments

Angulo

Manini

López

et al. 2021

Cancers

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is curable when diagnosed at an early stage, but when disease is non-confined it is the urologic cancer with worst prognosis. Antiangiogenic treatment and immune checkpoint inhibition therapy constitute a very promising combined therapy for advanced and metastatic disease. Many exploratory studies have identified epigenetic markers based on DNA methylation, histone modification, and ncRNA expression that epigenetically regulate gene expression in ccRCC. Additionally, epigenetic modifiers genes have been proposed as promising biomarkers for ccRCC. We review and discuss the current understanding of how epigenetic changes determine the main molecular pathways of ccRCC initiation and progression, and also its clinical implications. Despite the extensive research performed, candidate epigenetic biomarkers are not used in clinical practice for several reasons. However, the accumulated body of evidence of developing epigenetically-based biomarkers will likely allow the identification of ccRCC at a higher risk of progression. That will facilitate the establishment of firmer therapeutic decisions in a changing landscape and also monitor active surveillance in the aging population. What is more, a better knowledge of the activities of chromatin modifiers may serve to develop new therapeutic opportunities. Interesting clinical trials on epigenetic treatments for ccRCC associated with well established antiangiogenic treatments and immune checkpoint inhibitors are revisited.

show abstract

“…Moreover, they are involved in cell differentiation, growth, apoptosis, and proliferation [ 32 , 33 ]. MiRNA deregulation in cancer was first described in 2002 (chronic lymphocytic leukemia), and since then, it has been increasingly implicated in tumorigenesis [ 32 , 33 , 34 , 35 ].…”

Section: Micrornasmentioning

confidence: 99%

Unveiling the World of Circulating and Exosomal microRNAs in Renal Cell Carcinoma

Sequeira

Constâncio

Lobo

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Renal cell carcinoma is the third most common urological cancer. Despite recent advances, late diagnosis and poor prognosis of advanced-stage disease remain a major problem, entailing the need for novel early diagnosis tools. Liquid biopsies represent a promising minimally invasive clinical tool, providing real-time feedback of tumor behavior and biological potential, addressing its clonal evolution and representing its heterogeneity. In particular, the study of circulating microRNAs and exosomal microRNAs in liquid biopsies experienced an exponential increase in recent years, considering the potential clinical utility and available technology that facilitates implementation. Herein, we provide a systematic review on the applicability of these biomarkers in the context of renal cell carcinoma. Issues such as additional benefit from extracting microRNAs transported in extracellular vesicles, use for subtyping and representation of different histological types, correlation with tumor burden, and prediction of patient outcome are also addressed. Despite the need for more conclusive research, available data indicate that exosomal microRNAs represent a robust minimally invasive biomarker for renal cell carcinoma. Thus, innovative research on microRNAs and novel detection techniques are likely to provide clinically relevant biomarkers, overcome current clinical challenges, and improve patient management.

show abstract

Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs

Cited by 12 publications

References 197 publications

Role of Metabolic Reprogramming of Long non-coding RNA in Clear Cell Renal Cell Carcinoma

Role of Metabolic Reprogramming of Long non-coding RNA in Clear Cell Renal Cell Carcinoma

The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments

Unveiling the World of Circulating and Exosomal microRNAs in Renal Cell Carcinoma

Contact Info

Product

Resources

About